Vaxart, Inc. (VXRT) Form 424B5 — May 4, 2026
Vaxart, Inc. has filed a prospectus supplement to sell up to $49,772,479 of its common stock through an "at-the-market" offering agreement with Citizens JMP Securities, LLC and B. Riley Securities, Inc. The company disclosed that its recurring losses and negative cash flows raise substantial doubt about its ability to continue as a going concern, noting it was recently delisted from Nasdaq and now trades on the OTCQX Best Market.
Key figures
- Cash Position
- $63.8 million
- Gross Proceeds
- $49,772,479
- Offering Price
- $0.63
- Shares Outstanding
- 241414053
- Cash Runway
- Second quarter of 2027
- Dilution Per Share
- $0.23
- Shares Issuable Dilution
- 79003934
Price after filing
1 day: 0.0%7 days: -14.5%30 days: -21.1%
Close on the filing date to close N calendar days later (from $0.76). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.